secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001680367-24-000024
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Q1 net loss $18.5M, cash $114.6M; expects data at EHA June 2024
------------------------------------------------------------------------

- Net loss $18.5M ($0.37 per share) vs $20.7M ($0.49) in Q1 2023; R&D $16.3M, G&A $4.9M.
- Cash and investments $114.6M at March 31, 2024, down from $135.5M a year ago; cash runway into 2026.
- Phase 1B expansion for TP53m AML completed enrollment; randomized HR-MDS cohort expected Q2 2024; data at EHA June 2024.
- Appointed Clay Siegall, Ph.D., and Kate Sasser, Ph.D. to Board of Directors effective March 1, 2024.
- Entered collaboration with Ono Pharma for bifunctional fusion proteins in autoimmune/inflammatory diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036724000024/0001680367-24-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036724000024/sttk-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001680367-24-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer